However, due to pancreatic cancer's unique characteristics, the treatment of single immune checkpoint inhibitor, anti-CTLA-4, anti-PD-1, or anti-PD-L1, has shown minimal clinical benefits in the treatment of advanced PDAC. This evidence concerns the gene CD274 and familial pancreatic carcinoma.